Prosecution Insights
Last updated: November 20, 2026
Application No. 18/746,401

ANTIMICROBIAL PEPTIDES AND METHODS OF USING SAME

Non-Final OA §101§102§112§DOUBLEPATENT
Filed
Jun 18, 2024
Priority
Dec 07, 2017 — provisional 62/595,725 +3 more
Examiner
STEELE, AMBER D
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zoetis LLC
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
489 granted / 831 resolved
-1.2% vs TC avg
Moderate +10% lift
Without
With
+9.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
84 currently pending
Career history
895
Total Applications
across all art units

Statute-Specific Performance

§101
8.2%
-31.8% vs TC avg
§103
25.8%
-14.2% vs TC avg
§102
20.1%
-19.9% vs TC avg
§112
25.9%
-14.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 831 resolved cases

Office Action

§101 §102 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-49 were originally filed June 18, 2024. The preliminary amendment received June 18, 2024 canceled claims 1-21, 23, 31-33, 35, 40, and 42-49; amended claims 22, 34, 36-38, and 41; and added new claims 50-53. Please note: claims 37 and 38 should have a status identifier of “currently amended”. The status identifier for claim 41 is missing a parentheses. The amendment received October 23, 2026 amended claims 22 and 50. Please note: claims 24-30 should have the status identifier of “original”. The space in the status identifier for claim 39 should be removed (i.e. “(withdrawn )” should read “(withdrawn)”). Claims 22, 24-30, 34, 36-39, 41, and 50-53 are currently pending. Claims 22, 27, 28, 30, 51, and 52 are currently under consideration. Election/Restrictions Applicant’s election without traverse of Group I (claims 22, 24-30, and 50-53) in the reply filed on October 23, 2026 is acknowledged. Claims 34, 36-39, and 41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected methods, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on October 23, 2026. Applicant’s election of SEQ ID NO: 29 with the C-terminal D being replaced by E (i.e. single conservative amino acid substitution) in the reply filed on October 23, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 24-26, 29, 50, and 53 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on October 23, 2026. Potential Rejoinder Applicant elected claims directed to a product. If a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all the criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See “Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b),” 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to a rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01. Priority The present application is a CON of 17/738,572 filed May 6, 2022 (now U.S. Patent 12,054,518) which is a CON of 16/769,025 filed June 2, 2020 (now U.S. Patent 11,352,396) which is a 371 (National Stage) of PCT/US2018/064029 filed December 5, 2018 which claims the benefit of 62/695,725 filed December 7, 2017. Information Disclosure Statement The information disclosure statement (IDS) submitted on August 19, 2024 is being considered by the examiner, in part (see the crossed out citation which is missing a date). The information disclosure statement (IDS) submitted on March 2, 2026 is being considered by the examiner. Nucleotide and/or Amino Acid Sequence Disclosures Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures 37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted: 1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying: a. the name of the XML file b. the date of creation; and c. the size of the XML file in bytes; or 2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying: a. the name of the XML file; b. the date of creation; and c. the size of the XML file in bytes. SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS: Specific deficiency - Sequences appearing in the specification are not identified by sequence identifiers (i.e., “SEQ ID NO:X” or the like) in accordance with 37 CFR 1.831(c). See the abstract. Required response – Applicant must provide: A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required sequence identifiers, consisting of: • A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); • A copy of the amended specification without markings (clean version); and • A statement that the substitute specification contains no new matter. Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Objections Claim 22 is objected to because of the following informalities: personalization of inanimate objects is not typical in scientific writing (e.g. “its” should be “the”). Appropriate correction is required. Claim 22 is objected to because of the following informalities: a conjunction is missing between position 15 and position 17. Appropriate correction is required. Claim 22 is objected to because of the following informalities: a period is missing at the end of the claim. Appropriate correction is required. Claim 22 is objected to because of the following informalities: “at position” should read “at the position”. Appropriate correction is required. Claim 27 is objected to because of the following informalities: “at position” should read “at the position”. Appropriate correction is required. Claim 28 is objected to because of the following informalities: “at position” should read “at the position”. Appropriate correction is required. Claim 30 is objected to because of the following informalities: “by three, two, or one” should read “by one, two, or three”. Appropriate correction is required. Claim 52 is objected to because of the following informalities: “at position” should read “at the position”. Appropriate correction is required. Sequence Interpretation The Office interprets claims comprising SEQ ID NOs: in the following manner: “comprising a sequence of SEQ ID NO: 1” requires only a 2mer of SEQ ID NO: 1, “comprising the sequence of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 with any N-/C-terminal additions or any 5’/3’ additions, “consisting of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 and the same length as SEQ ID NO: 1, and “selected from the group consisting of SEQ ID NOs: 1, 2, and 3” requires the full-length sequence with 100% identity to SEQ ID NOs: 1, 2, or 3 and the same length as SEQ ID NOs: 1, 2, or 3. Any claim requiring a specific percent identity, necessarily requires at least the recited percent identity. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 22, 27, 28, 30, and 51 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the present peptide. For example, it is unclear if only 1-3 amino acids may differ from SEQ ID NO: 1 or SEQ ID NO: 29; if the D18E mutation is one of the differing amino acids; if the optional 1-2 differing amino acids are part of the 1-3; etc. Is the D18E mutation required or can that residue be one that differs in another way? Are 3 differences the maximum or are 6 differences the maximum (e.g. 1-3 differences, D18E, and 1-2 additional differences)? Regarding the length limitation, one to potentially six “differences” may be present including deletions. Claim 30 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the present peptide. For example, it is unclear if the 1-3 differences are the same as present claim 22 or not. It is also unclear if this includes D18E. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 30 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 30 is dependent on independent claim 22. Independent claim 22 requires 1-3 differences, a D18E mutation, and optional 1-2 differences. Dependent claim 30 requires 1-3 differences. Thus, it appears that the 1-3 differences do not require a D18E mutation. Therefore, claim 30 fails to further limit independent claim 22. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 22, 27, 28, and 30 are rejected under 35 U.S.C. 101 because the claimed invention is directed to tachyplesin (KWCFRVCYRGICYRRCR) or polyphemusin (RRWCFRVCYRGFCYRKCR) without significantly more. The claims recite SEQ ID NO: 1 (KWCFRVCYRGICYRRCRD) and SEQ ID NO: 29 (PKWCFRVCYRGICYRRCRD) with 1-3 differences (and potentially up to six differences). This judicial exception is not integrated into a practical application because the present claims are drawn to the peptide only. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the claims are drawn to the peptide only. See Nakamura et al., 1988, Tachyplesin, a Class of Antimicrobial Peptide from the Hemocytes of the Horseshoe Crab (Tachypleus tridentatus), The Journal of Biological Chemistry, 263(32): 16709-16713 and Powers et al., 2004, Structure-activity relationships for the b-hairpin cationic antimicrobial peptide polyphemusin I, Biochimica et Biophysica Acta, 1698: 239-250. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 22, 27, 28, and 30 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Nakamura et al., 1988, Tachyplesin, a Class of Antimicrobial Peptide from the Hemocytes of the Horseshoe Crab (Tachypleus tridentatus), The Journal of Biological Chemistry, 263(32): 16709-16713. For present claims 22, 27, 28, and 30, Nakamura et al. teach tachyplesin (KWCFRVCYRGICYRRCR) (please refer to the entire reference particularly the abstract; Figure 1). Therefore, the teachings of Nakamura et al. anticipate the present peptide. Claims 22, 27, 28, and 30 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Doherty et al., 2006, Peptide-lipid interactions of the b-hairpin antimicrobial peptide tachyplesin and its linear derivatives from solid-state NMR, Biochimica et Biophysica Acta, 1758: 1285-1291. For present claims 22, 27, 28, and 30, Doherty et al. teach tachyplesin (KWCFRVCYRGICYRRCR) (please refer to the entire reference particularly Figure 1). Therefore, the teachings of Doherty et al. anticipate the present peptide. Claims 22, 27, 28, and 30 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Powers et al., 2004, Structure-activity relationships for the b-hairpin cationic antimicrobial peptide polyphemusin I, Biochimica et Biophysica Acta, 1698: 239-250. For present claims 22, 27, 28, and 30, Powers et al. teach tachyplesin (KWCFRVCYRGICYRRCR) and polyphemusin (RRWCFRVCYRGFCYRKCR) (please refer to the entire reference particularly the Introduction; Figure 1; sections 2.2) Therefore, the present peptide is anticipated by the teachings of Powers et al. Claims 22, 27, 28, and 30 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fujii et al. U.S. Patent 5,449,752 issued September 12, 1995. For present claims 22, 27, 28, and 30, Fujii et al. teach tachyplesin (KWCFRVCYRGICYRRCR) and polyphemusin (RRWCFRVCYRGFCYRKCR) and variants thereof (please refer to the entire specficiation particularly the abstract; Figure 1; columns 1, 2, 5, 6, 9, 10; Tables I, III, IV) Therefore, the present peptide is anticipated by the teachings of Fujii et al. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 22, 27, 28, 30, 51, and 52 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 12,054,518. Although the claims at issue are not identical, they are not patentably distinct from each other because both the present claims and the claims of U.S. Patent No. 12,054,518 are drawn to peptides which vary by 1-3 amino acids from present SEQ ID NOs: 1 or 29. Claims 22, 27, 28, 30, 51, and 52 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 11,352,396. Although the claims at issue are not identical, they are not patentably distinct from each other because both the present claims and the claims of U.S. Patent No. 11,352,396 are drawn to peptides which vary by 1-3 amino acids from present SEQ ID NOs: 1 or 29. Future Communications Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMBER D STEELE whose telephone number is (571)272-5538. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMBER D STEELE/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Jun 18, 2024
Application Filed
Nov 05, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778873
PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION
4y 4m to grant Granted Nov 03, 2026
Patent 12760298
TECHNOLOGIES USEFUL FOR ASSESSING PERMEABILITY
4y 4m to grant Granted Oct 13, 2026
Patent 12760072
BROAD-SPECTRUM ANTIVIRAL PEPTIDES
4y 0m to grant Granted Oct 13, 2026
Patent 12760069
COMPOUNDS TARGETING ALPHA4-BETA7 INTEGRIN
3y 9m to grant Granted Oct 13, 2026
Patent 12758611
COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-beta
2y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
68%
With Interview (+9.6%)
3y 5m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 831 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month